CN104114169A - 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 - Google Patents

用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 Download PDF

Info

Publication number
CN104114169A
CN104114169A CN201280066423.2A CN201280066423A CN104114169A CN 104114169 A CN104114169 A CN 104114169A CN 201280066423 A CN201280066423 A CN 201280066423A CN 104114169 A CN104114169 A CN 104114169A
Authority
CN
China
Prior art keywords
methyl
acetic acid
fluoro
indole
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280066423.2A
Other languages
English (en)
Chinese (zh)
Inventor
马克·安东尼·佩顿
埃里克·罗伊·佩蒂弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atropic Is Worn And This Treats Co Ltd
Original Assignee
Atropic Is Worn And This Treats Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atropic Is Worn And This Treats Co Ltd filed Critical Atropic Is Worn And This Treats Co Ltd
Publication of CN104114169A publication Critical patent/CN104114169A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201280066423.2A 2011-12-16 2012-12-14 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 Pending CN104114169A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576640P 2011-12-16 2011-12-16
US61/576,640 2011-12-16
PCT/GB2012/000904 WO2013088109A1 (en) 2011-12-16 2012-12-14 Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis

Publications (1)

Publication Number Publication Date
CN104114169A true CN104114169A (zh) 2014-10-22

Family

ID=47470031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280066423.2A Pending CN104114169A (zh) 2011-12-16 2012-12-14 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物

Country Status (14)

Country Link
US (1) US20140328861A1 (enExample)
EP (1) EP2790696A1 (enExample)
JP (1) JP2015500326A (enExample)
KR (1) KR20140113667A (enExample)
CN (1) CN104114169A (enExample)
AU (1) AU2012351342A1 (enExample)
BR (1) BR112014014558A8 (enExample)
CA (1) CA2859284A1 (enExample)
EA (1) EA026456B1 (enExample)
IL (1) IL233131A0 (enExample)
MX (1) MX2014007239A (enExample)
SG (1) SG11201402796SA (enExample)
UA (1) UA112667C2 (enExample)
WO (1) WO2013088109A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014869A1 (zh) * 2016-07-21 2018-01-25 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚衍生物
CN107936004A (zh) * 2017-11-30 2018-04-20 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类衍生物
CN107954995A (zh) * 2017-11-30 2018-04-24 正大天晴药业集团股份有限公司 具有crth2抑制剂活性的吲哚衍生物
CN107987066A (zh) * 2017-11-30 2018-05-04 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚衍生物
CN107987072A (zh) * 2017-11-30 2018-05-04 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类化合物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
RU2690675C2 (ru) 2012-08-21 2019-06-05 Санофи Байотекнолоджи Способы лечения или предотвращения астмы посредством введения антагониста il-4r
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
EP3613432B1 (en) 2013-06-21 2025-08-06 Sanofi Biotechnology Methods for treating nasal polyposis by administering an il-4r antagonist
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP4442323A3 (en) 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR20250044796A (ko) 2017-10-30 2025-04-01 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
PH12021552123A1 (en) 2019-03-21 2022-08-22 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
WO2022020464A1 (en) * 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors
EP4595953A1 (en) * 2024-01-30 2025-08-06 Dr. Falk Pharma Gmbh Orally applicable suspension for the treatment of eosinophilic esophagitis in children

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042652A2 (en) * 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003097042A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Pgd2 receptor antagonist
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
KR20050055747A (ko) 2002-10-04 2005-06-13 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료용의 ｐｇｄ2 수용체 길항제
ES2263015T3 (es) 2002-10-21 2006-12-01 Warner-Lambert Company Llc Derivados de tetrahidroquinolina como antagonistas de crth2.
EP1585511B1 (en) 2002-12-20 2013-01-23 Amgen Inc. Asthma and allergic inflammation modulators
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
US20050038070A1 (en) 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
RU2006109108A (ru) 2003-10-14 2007-11-20 Оксаген Лимитед (GB) Соединения, обладающие активностью антагонистов crth2 рецепторов
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
NZ548396A (en) 2004-01-31 2010-06-25 Actimis Pharmaceuticals Inc Imidazo[1,2-C]pyrimidinylacetic acid derivatives
KR101165863B1 (ko) 2004-03-11 2012-07-13 액테리온 파마슈티칼 리미티드 인돌-1-일-아세트산 유도체
WO2005095397A1 (en) 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
MXPA06011540A (es) 2004-04-07 2007-01-26 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
CA2568742A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Substituted thiazoleacetic as crth2 ligands
JP2008500991A (ja) 2004-05-29 2008-01-17 ７ティーエム ファーマ エイ／エス 医学的使用のためのｃｒｔｈ２レセプターリガンド
US20090105218A1 (en) 2004-05-29 2009-04-23 7Tm Pharma A/S CRTH2 Receptor Ligands For Therapeutic Use
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
EA200700712A1 (ru) 2004-09-21 2008-02-28 Эсерсис, Инк. Производные индолуксусной кислоты, способ получения таких производных (варианты), фармацевтическая композиция, набор на их основе, способ ингибирования связывания эндогенных лигандов и способ лечения заболеваний и расстройств, восприимчивых к ингибированию связывания эндогенных лигандов с рецептором crth-2
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
JP2008543726A (ja) 2005-02-24 2008-12-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の処置のためのｐｇｄ２受容体アンタゴニスト
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
RU2453540C2 (ru) 2005-04-21 2012-06-20 Лаборатуар Сероно С.А. 2,3-замещенные пиразинсульфонамиды в качестве ингибиторов crth2
GB0510585D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
PT1891075E (pt) 2005-05-24 2011-11-10 Merck Serono Sa Derivados espiro tricíclicos como moduladores do crth2
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
ATE425791T1 (de) * 2005-07-29 2009-04-15 Rottapharm Spa Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten
EP1915372B1 (en) 2005-08-12 2013-11-20 Merck Canada Inc. Indole derivatives as crth2 receptor antagonists
WO2007022501A2 (en) 2005-08-18 2007-02-22 Microbia, Inc. Useful indole compounds
GB0518494D0 (en) 2005-09-09 2005-10-19 Argenta Discovery Ltd Thiazole compounds
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
EP1928457B1 (en) 2005-09-30 2012-12-12 Pulmagen Therapeutics (Asthma) Limited Quinolines and their therapeutic use
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
JP2009514935A (ja) 2005-11-05 2009-04-09 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007062678A1 (en) 2005-11-29 2007-06-07 7Tm Pharma A/S Phenoxyacetic acid derivatives as crth2 receptor ligands
GB0524427D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Use of receptor ligands in threapy
WO2007062677A1 (en) 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
US20080293775A1 (en) 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
CN101454284A (zh) 2006-05-26 2009-06-10 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
GB0611781D0 (en) 2006-06-14 2006-07-26 Argenta Discovery Ltd 2-Oxo-2H-Chromene Compounds
EP2046740B1 (en) 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
NZ575507A (en) 2006-08-21 2011-10-28 Array Biopharma Inc 4-substituted phenoxyphenylacetic acid derivatives
CA2673356A1 (en) 2006-12-21 2008-06-26 Argenta Discovery Limited Crth2 antagonists
GB0625842D0 (en) 2006-12-22 2007-02-07 Argenta Discovery Ltd Indolizine derivatives
AU2007349641A1 (en) 2007-03-21 2008-09-25 Argenta Oral Therapeutics Limited Indolizine acetic acid derivatives as CRTH2 antagonists
EP2129661B1 (en) 2007-03-29 2012-02-08 Pulmagen Therapeutics (Asthma) Limited Quinoline derivatives as crth2 receptor ligands
CN101772489B (zh) 2007-06-21 2013-02-20 艾克提麦斯医药品有限公司 一种crth2拮抗剂的胺盐
US20110124683A1 (en) 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
GB0722216D0 (en) * 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
ATE502920T1 (de) * 2007-12-14 2011-04-15 Pulmagen Therapeutics Asthma Ltd Indole und ihre therapeutische verwendung
EA201001029A1 (ru) 2007-12-19 2011-06-30 Амген Инк. Производные фенилуксусной кислоты в качестве модуляторов процесса воспаления
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
MX2010007833A (es) * 2008-01-18 2010-08-11 Oxagen Ltd Compuestos que tienen actividad antagonista de crth2.
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
JP2011509990A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
EP2300425A4 (en) * 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
US20110312945A1 (en) * 2008-10-01 2011-12-22 James Jia Crth2 modulators
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
IN2012DN00359A (enExample) * 2009-07-20 2015-05-22 Vetegen Llc
SG10201404662YA (en) 2009-08-05 2014-10-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
RU2015138677A (ru) * 2009-08-17 2018-12-25 Дзе Пенн Стейт Рисерч Фаундейшн Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа
AU2011203649A1 (en) 2010-01-06 2012-06-14 Brickell Biotech, Inc. DP2 antagonist and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042652A2 (en) * 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAVIER MOLINA INFANTE ET AL: "Esophageal Eosinophilic Infiltration Responds to Proton Pump Inhibition in Most Adults", 《CLINICAL GASTROENTEROLOGY AND HEPATOLOGY》, vol. 9, no. 2, 28 February 2011 (2011-02-28), XP028187339, DOI: doi:10.1016/j.cgh.2010.09.019 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014869A1 (zh) * 2016-07-21 2018-01-25 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚衍生物
US10800765B2 (en) 2016-07-21 2020-10-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indole derivative used as CRTH2 inhibitor
CN107936004A (zh) * 2017-11-30 2018-04-20 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类衍生物
CN107954995A (zh) * 2017-11-30 2018-04-24 正大天晴药业集团股份有限公司 具有crth2抑制剂活性的吲哚衍生物
CN107987066A (zh) * 2017-11-30 2018-05-04 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚衍生物
CN107987072A (zh) * 2017-11-30 2018-05-04 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类化合物
CN107954995B (zh) * 2017-11-30 2020-05-05 正大天晴药业集团股份有限公司 具有crth2抑制剂活性的吲哚衍生物
CN107936004B (zh) * 2017-11-30 2020-05-05 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类衍生物

Also Published As

Publication number Publication date
KR20140113667A (ko) 2014-09-24
MX2014007239A (es) 2014-08-08
SG11201402796SA (en) 2014-06-27
BR112014014558A8 (pt) 2017-07-04
EA026456B1 (ru) 2017-04-28
CA2859284A1 (en) 2013-06-20
IL233131A0 (en) 2014-07-31
NZ626990A (en) 2016-01-29
EA201491008A1 (ru) 2015-02-27
BR112014014558A2 (pt) 2017-06-13
EP2790696A1 (en) 2014-10-22
US20140328861A1 (en) 2014-11-06
AU2012351342A1 (en) 2014-07-24
WO2013088109A1 (en) 2013-06-20
JP2015500326A (ja) 2015-01-05
UA112667C2 (uk) 2016-10-10

Similar Documents

Publication Publication Date Title
CN104114169A (zh) 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
JP2023052343A (ja) インダゾール－３－カルボキサミドの使用方法およびｗｎｔ／β－カテニンシグナル伝達経路阻害剤としてのそれらの使用
JP6378409B2 (ja) １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびそれらの治療的使用
JP2015500326A5 (enExample)
TWI793191B (zh) Ｐ３８激酶抑制劑減少ｄｕｘ４及下游基因表現以供治療ｆｓｈｄ
JP6342393B2 (ja) 置換型ピラゾロン化合物及び使用方法
US20130052190A1 (en) CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
RU2020112759A (ru) Гетероциклические соединения в качестве ингибиторов PAD
WO2015002754A2 (en) Novel bicyclic bromodomain inhibitors
US20190070159A1 (en) Novel pharmaceutical uses
JP2000198734A (ja) 胃運動性減弱および関連疾患の治療のための運動性増強薬
CA2524268A1 (en) Proton pump inhibitors for the treatment of lower abdominal disorders
TW202523323A (zh) 用於治療慢性心臟衰竭的吡唑並〔３，４－ｄ〕嘧啶酮化合物
TW202448460A (zh) Dgk（二醯基甘油激酶）抑制劑之組合
US20050165041A1 (en) Combination for the treatment of airway disorders
NZ626990B2 (en) Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2025132549A1 (en) Cancer combination therapy using zongertinib and a kras g12c inhibitor
JP2005523298A (ja) 非心臓性胸痛の治療のためのプロトンポンプ阻害剤の使用
JP2005522462A (ja) 気道疾患の治療のためのプロトンポンプ阻害剤の使用
CN118632696A (zh) 包含fgfr抑制剂和kras抑制剂的组合疗法
RU2023127295A (ru) Производные индолина в качестве ингибиторов ddr

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141022